VK-2019 clinical trials
Also written VK-2019.
How each study uses VK-2019 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the VK-2019 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- VK-2019
- 3
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Stanford University (1) · Pierluigi Porcu (1) · Cullinan Therapeutics Inc. (1)
Studies
Open first, then newest update. How each study uses VK-2019 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)RecruitingPhase 1Pierluigi PorcuNCT06789159Written as VK-2019
- Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative StudiesActive, not recruitingPhase 2Stanford UniversityNCT04925544Written as VK-2019
- Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)TerminatedPhase 1/2Cullinan Therapeutics Inc.NCT03682055Written as VK-2019
Codes
What other systems call VK-2019 · ClinicalTrials.gg INT018215
- UNII (FDA) V6WN54K07KVK-2019One source FDA
- NCI Thesaurus C159410EBNA-1 inhibitor VK-2019One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | V6WN54K07K | VK-2019 | One source FDA |
| NCI Thesaurus | C159410 | EBNA-1 inhibitor VK-2019 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.